REVIVA PHARMACEUTICALS HOLDI (RVPH)
US76152G1004 - Common Stock
RVPH Stock Earnings: Reviva Pharmaceuticals Misses EPS for Q4 2023
RVPH stock results show that Reviva Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.
RVPH Stock Earnings: Reviva Pharmaceuticals Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Reviva Pharmaceuticals (NASDAQ:RVPH) just reported results for the fourth quart...
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
- FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have...
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
– RECOVER-1 Phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia –
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting
CUPERTINO, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
Reviva to Present at the UBS Virtual CNS Day
CUPERTINO, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
CUPERTINO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
Reviva Pharmaceuticals files for $200M mixed securities shelf (NASDAQ:RVPH)
Reviva Pharmaceuticals files a prospectus for the sale of $200M mixed securities shelf, emphasizing that it is not an offer to sell.
Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference
CUPERTINO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) (
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
These three companies are developing treatments for brain diseases that have a great deal of potential, making them top neuroscience stocks.
Life Science Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
Life Science Investor Forum Agenda Announced for December 14th, 2023
Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum
Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum
CUPERTINO, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
AbbVie – Cerevel deal lifts Reviva, Karuna (NASDAQ:RVPH)
AbbVie's (ABBV) $8.7B deal to buy Cerevel Therapeutics (CERE) boosts neurology-focused biopharmas Reviva Pharma (RVPH) and Karuna Therapeutics (KRTX). Read more here.
Reviva Pharmaceuticals to Participate in The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
CUPERTINO, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO, and Narayan Prabhu, CFO of Reviva, will participate in The Benchmark Company’s Discovery One-on-One Investor Conference, taking place December 7, 2023 in New York, NY.
Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
CUPERTINO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
Reviva Pharma stock slips on $30M share sale (NASDAQ:RVPH)
Reviva Pharmaceuticals (RVPH) fell ~6% Thursday after announcing agreements to sell ~5.9M shares of its common stock and warrants to raise $30M. Read more here.
Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights
- RECOVER global Phase 3 trial successfully met all primary and secondary endpoints with statistically significant and clinically meaningful reductions...
Analyst Assessment On Reviva Pharmaceuticals' Positive Schizophrenia Trial Data - Sees More Than 200% Upside In Stock
Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) shares are surging after the company released topline results of its pivotal Phase 3 RECOVER trial evaluating brilaroxazine, a serotonin-dopamine signaling modulator in
Monday Sector Leaders: Drugs, Education & Training Services
Reviva posts late-stage data for schizophrenia candidate
Reviva Pharmaceuticals (RVPH) on Monday reported positive results from its Phase 3 trial for schizophrenia drug brilaroxazine. Read more here.
Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
- Successfully met primary endpoint; brilaroxazine 50 mg delivered a statistically significant and clinically meaningful 10.1-point reduction in Positive...
Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia
Topline data for RECOVER trial on track for October 2023...
Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
CUPERTINO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for another dive into the biggest pre-market stock movers this morning as we check out the latest news on Thursday!
Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia
- 402 patients completed enrollment across multiple sites in the US, Europe, and Asia – - Topline data for Phase 3 RECOVER study expected in October 2023...
Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- Topline data for global pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected in October 2023 - - Completion of 1-year...